{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:40:35Z","timestamp":1788172835787,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,7]]},"abstract":"<jats:p>In this Blood Spotlight, the authors review the appropriate clinical background, mechanism of action, and detailed therapeutic data about duvelisib in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and follicular lymphoma.<\/jats:p>","DOI":"10.1182\/blood.2019001795","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T20:25:31Z","timestamp":1569443131000},"page":"1573-1577","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"134","author":[{"given":"Krish","family":"Patel","sequence":"first","affiliation":[{"name":"Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Knight Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"issue":"4","key":"2019111522025455800_B1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"11","key":"2019111522025455800_B2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"issue":"1","key":"2019111522025455800_B3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111522025455800_B4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"2019111522025455800_B5","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111522025455800_B6","doi-asserted-by":"crossref","first-page":"e0200725","DOI":"10.1371\/journal.pone.0200725","article-title":"The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"issue":"13","key":"2019111522025455800_B7","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111522025455800_B8","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"2019111522025455800_B9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajh.25243","article-title":"Duvelisib, an oral dual PI3K-\u03b4,\u03b3 inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study","volume":"93","author":"O\u2019Brien","year":"2018","journal-title":"Am J Hematol"},{"issue":"23","key":"2019111522025455800_B10","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2019111522025455800_B11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111522025455800_B12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111522025455800_B13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111522025455800_B14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"35","key":"2019111522025455800_B15","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111522025455800_B16","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood.V128.22.2979.2979","article-title":"Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-\u03b4,\u03b3 inhibitor, duvelisib, in combination with rituximab or obinutuzumab","volume":"128","author":"Casulo","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111522025455800_B17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/annonc\/mdv375","article-title":"Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study","volume":"26","author":"Casulo","year":"2015","journal-title":"Ann Oncol"},{"issue":"22","key":"2019111522025455800_B18","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111522025455800_B19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"issue":"14","key":"2019111522025455800_B20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522025455800_B21","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"2019111522025455800_B22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/19\/1573\/1505316\/bloodbld2019001795c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/19\/1573\/1505316\/bloodbld2019001795c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:46Z","timestamp":1573862446000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/19\/1573\/375003\/Duvelisib-for-CLLSLL-and-follicular-nonHodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":22,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,9,25]]},"published-print":{"date-parts":[[2019,11,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001795","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]}}}